

**FHS PUBLIC ACCESS****Author manuscript**

Nat Genet. Author manuscript; available in PMC 2018 June 22.

Published in final edited form as:

Nat Genet. 2018 January ; 50(1): 42–53. doi:10.1038/s41588-017-0014-7.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence should be sent to: Florence Demenais, Genetic Variation and Human Diseases Unit, UMR-946, INSERM-Université Paris Diderot, 27 rue Juliette Dodu, 75010 Paris, France, Phone : +33 1 72 63 93 02 – Fax : +33 01 72 63 93 49 - florence.demenais@inserm.fr or Dan Nicolae, Departments of Statistics, The University of Chicago, 5734 S. University Avenue, Chicago, IL 60637, USA, Phone: +1 773 702 4837 - Fax: +1 773 702 9810 - nicolae@galton.uchicago.edu.

*These authors contributed equally to this work

URLS

National Human Genome Research Institute (NHGRI) and European Bioinformatics Institute (EBI) catalog of published genome-wide association, <https://www.ebi.ac.uk/gwas/>; 1000 Genomes Project Consortium Phase 3, <http://www.internationalgenome.org/>; Genome-wide Complex Trait Analysis (GCTA), <http://cns.genomics.com/software/gcta>; Blood-eQTL database, <https://omictools.com/blood-eqtl-browser-tool>; GTEx, <http://www.gtexportal.org/>; MuTHER database, <http://www.muther.ac.uk/>; eQTL database in lymphoblastoid cell lines from MRCA and MRCE families, <https://www.hshp.harvard.edu/liming-liang/software/eqtl/>; GHS_Express, <http://genecanvas.ecgene.net/>; HaploReg v4.1, <http://archive.broadinstitute.org/mammals/haploreg/haploreg.php>; ROADMAP and ENCODE epigenomics data, http://egg2.wustl.edu/roadmap/web_portal/; Uncovering Enrichment through Simulation (UES) pipeline, <https://github.com/JamesHayes/uesEnrichment>; GRAIL, <https://software.broadinstitute.org/mpg/grail/>; VIZGRAIL, <http://software.broadinstitute.org/mpg/grail/vizgrail.html>; LocusZoom, <http://locuszoom.org/>

AUTHOR CONTRIBUTIONS

TAGC study management: F.D., K.C.B., W.O.C.C., M.F.M., C.O., D.L.N.

F.D. and D.L.N. designed the study and wrote the manuscript. F.D., D.L.N., P.M-J designed and conducted the statistical analysis. K.C.B., W.O.C.C., M.F.M., C.O. designed the study and wrote the manuscript. M.B., A.V., S.L., H.M. carried out the quality control of the data and performed statistical analysis.

AAGC (Australia): Study PIs: M.A.F., M.C.M., C.F.R., P.J.T.; Data collection or analysis: M.A.F., M.C.M., C.F.R., G.J., P.J.T.

ALLERGEN CAPPS and SAGE: Study PIs: A.B.B., M.C.-Y., D.D., A.L.K.; Data collection or analysis: D.D., J.E.P.; Study Phenotyping: A.B.B., M.C.-Y.

SLSJ: Study PIs: C.L., T.J.H.; Study design and management: C.L.

APCAT Consortium: Study PIs: J.N.H., M.R.J., V.S.; **FHS:** Study PI: G.T.O.; Data collection or analysis: S.V., Z.G.; **EPIC-Norfolk:**

Study PI: N.J.W.; Data collection or analysis: J.H.Z., R.S.; **NFBC1966:** Study PI: M.R.J.; Data collection or analysis: A.C.A., A.R.;

FINRISK: Study PI: V.S.; Data collection or analysis: M.K., T.L.; **H2000:** Study PIs: M.H., P.J.; Data collection or analysis: M.K.,

T.H.; **HBSC:** Study PIs J.G.E.; Data collection or analysis: E.W., A.P.; **YFS:** Study PI: O.T.R.; Data collection or analysis: T.L., M.K.

CARE Consortium: Study PIs: J.N.H., S.S.R.; Data collection or analysis: C.D.P, D.B.K, L.J.S., R.K., K.M.B., W.B.W.

MESA: Study PIs: R.G.B, S.S.R.; Data collection or analysis: K.M.D, A.M.

ARIC: Study PI: S.J.L.; Data collection or analysis: S.J.L., L.R.L.

CHS: Study PIs: S.A.G., S.R.H.; Data collection or analysis: G.L., S.A.G., S.R.H.

deCode Genetics: Study PIs: K.S., I.J., D.F.G., U.T., G.T.; Data collection or analysis: I.J., D.F.G., G.T.; Study Phenotyping: U.S.B.

EAGLE Consortium: PI: H.B. **COPSAC:** Study PIs: H.B, K.B.; Data analysis: E.K., J.W.; Study Phenotyping: K.B.; **DNBC:** Study

PI: M.M.; Data collection or analysis: B.F and F.G.; **GENERATION R:** Study PI: J.C.dJ.; Data collection or analysis: R.J.P.vdV.,

L.D. and V.W.V.J. **GINIplus/LISAPlus:** Study PI: J.H.; Genotyping, data collection or analysis: M.S., C.M.T.T.; Study Phenotyping:

J.H.; **MAAS:** Study PIs: A.S., AC.; Data collection or analysis: J.A.C.; **RAINE:** Study PI: P.H.; Data collection or analysis:

W.A.,C.E.P.

B58C: PI and Statistical Analysis: D.P.S.

EVE: Study-Pis: C.O., D.L.N., K.C.B., E.B., E.B., J.G., F.G., S.J.L., F.J.M., D.M., I.R., S.T.W., L.K.W., B.A.R.; Data collection or

analysis: D.L.N., J.G., S.J.L., D.M., D.G.T., B.A.R., B.E.H., P.E.G., M.T.S., C.E., B.E.D., J.J.Y., A.M.L., R.A.M., R.A.M., T.H.B.

JAARC: Study PI: T.T.; Data collection or analysis: T.T., A.T., M.K.

JPAC: Study PI: E.N.; Data collection or analysis: H.H., K.M.

GABRIEL CONSORTIUM: Study PIs: W.O.C.C., E.V.M.; Genotyping: M.L.; Data Analysis: E.B., F.D., M.F., D.P.S. **EGEA:** Study

PIs: V.S., F.D.; Genotyping, data collection or analysis: M.L., E.B.; **ALSPAC:** Study PI: J.H.; Genotyping, data collection or analysis:

W.L.M., R.G.; Study phenotyping: J.H.; **ECRHS:** Study PI: D.J.; Data collection or analysis: C.J., J.H.; **BAMSE:** Study PIs: EM,

M.W., G.P.; **BUSSELTON:** Study PIs: A.W.M., A.J., J.B.; Genotyping, data collection or analysis: A.W.M., A.J., J.H., J.B.;

GABRIEL Advanced Studies: Study PI: E.V.M.; Data collection or analysis: M.K., J.G.; **KSMU:** Study PI: A.P.; Data collection or

analysis: M.S., V.I.; **MRCA-UKC:** Study PIs: W.O.C.C., M.M.; Data collection or analysis: L.L.; **MAGICS:** Study PI: MK; Data

collection or analysis: A.V.B., S.M.; **MAS:** Study PI: Y.L.; Data collection or analysis: S.L., I.M.; **PIAMA:** Study PI: G.H.K., D.S.P.;

Data collection or analysis: G.H.K., D.S.P., U.G.; **SAPALDIA:** Study PI: N.P.H.; Data collection or analysis: M.I., A.K. **TOMSK:**

Study PIs: L.M.O., V.P.P.; Data collection or analysis: M.B.F., P.A.S.; **UFA:** Study PI: E.K.; Data collection or analysis: A.S.K., Y.F.

INDUSTRIAL: Study PIs: D.H., T.S.; Data collection or analysis: I.M.W., V.S.; **SEVERE:** Study PIs: A.B., K.F.C., C.E.B.

NTR: Study PI: D.I.B.; Genotyping, data collection or analysis: J.J.H., H.M., G.W.

Rotterdam: Study PIs: A.H., B.H.S., G.G.B.; Genotyping, data collection or analysis: G.G.B., B.H.S., D.W.L., L.L., A.G.U.

DAGC: Study PIs: G.H.K., D.S.P.; Genotyping, data collection or analysis: G.H.K., D.S.P., J.A., M.A.E.N., J.M.V.

All authors provided critical review of the manuscript.

COMPETING FINANCIAL INTERESTS

Multiancestry association study identifies new asthma risk loci that colocalize with immune cell enhancer marks

A full list of authors and affiliations appears at the end of the article.

Abstract

We examined common variation in asthma risk by conducting a meta-analysis of worldwide asthma genome-wide association studies (23,948 cases, 118,538 controls) from ethnically-diverse populations. We identified five new asthma loci, uncovered two additional novel associations at two known asthma loci, established asthma associations at two loci implicated previously in comorbidity of asthma plus hay fever, and confirmed nine known loci. Investigation of pleiotropy showed large overlaps in genetic variants with autoimmune and inflammatory diseases. Enrichment of asthma risk loci in enhancer marks, especially in immune cells, suggests a major role of these loci in the regulation of immune-related mechanisms.

Asthma is a complex disease affecting hundreds of millions of people worldwide. Asthma prevalence varies between populations and ethnicities, ranging in the U.S. from 3.9% in Mexican Americans to 12.5% in African Americans¹. The contribution of genetic factors to asthma risk has been demonstrated in family studies, where heritability estimates range from 25%-80%². The large variability in prevalence and heritability estimates reflects the role of environmental exposures on disease risk and phenotypic heterogeneity that are hallmarks of asthma. These features may explain why genome-wide association studies (GWAS) have uncovered a smaller number of asthma loci than similarly sized studies of other multifactorial diseases³. Indeed, at the time of analysis, only 21 loci have been associated with asthma *per se* in 20 studies, and these loci explain only part of the genetic risk. Although an exome-chip study showed no evidence for low frequency or rare variants with large effects on asthma risk⁴, the role of noncoding rare variants in asthma remains unknown. Future studies based on whole-genome sequencing may clarify the respective influence of common and rare variants on asthma risk. To generate larger sample sizes for GWAS meta-analysis of asthma enabling the discovery of common novel risk loci, we established the Trans-National Asthma Genetic Consortium (TAGC) across worldwide groups of investigators with genome-wide data available in >142,000 individuals of diverse ancestries. We constructed a comprehensive catalog of asthma risk variants that are robust across populations and environmental exposures. By combining TAGC meta-analysis results with existing databases, we assessed the genetic architecture of asthma risk alleles with respect to functional effects and shared effects with other diseases.

The authors who are affiliated with deCODE (D.F.G., I.J., K.S., U.T., G.T.) are employees of deCODE genetics/AMGEN. All other co-authors did not declare any conflict of interest

RESULTS

Meta-analysis of asthma GWAS

We combined data from asthma GWAS with high-density genotyped and imputed SNP data (2.83 million SNPs) in the following populations: European-ancestry (19,954 cases, 107,715 controls), African-ancestry (2,149 cases, 6,055 controls), Japanese (1,239 cases, 3,976 controls) and Latino (606 cases, 792 controls) (Supplementary Table 1). After extensive QC of summary data provided by each participating group (Online Methods, Supplementary Note and Supplementary Table 2), we first conducted ancestry-specific meta-analyses followed by a multi-ancestry meta-analysis of all populations (23,948 cases, 118,538 controls) to identify additional loci with pan-ancestry effects. Because childhood-onset asthma may be distinct from later-onset asthma⁵ and may represent a more homogeneous subgroup, we also performed analyses on the pediatric subgroup (asthma onset < 16 years; 8,976 cases, 18,399 controls). Meta-analyses of SNP effect sizes obtained from each asthma GWAS were performed using fixed-effects (significance of the combined SNP effect size summarized in P_{fixed}) and random-effects (P_{random}) models (Online Methods) and using a conventional P_{random} (or P_{fixed}) threshold of 5×10^{-8} to define genome-wide significance. Results were consistent between methods for detecting loci with at least one SNP significantly associated with asthma. We therefore present the results from the random-effects analysis for the European-ancestry and multi-ancestry meta-analyses, which include the largest number of studies and allow an accurate estimate of the between-study variance, and results from the fixed-effects analysis for the African-ancestry, Japanese and Latino meta-analyses. We observed little evidence of inflation in the test statistics in either the ancestry-specific (lambda: European-ancestry, 1.031; African-ancestry, 1.014; Japanese, 1.021; Latino, 1.044) or multi-ancestry (lambda=1.046) meta-analyses (Supplementary Fig. 1).

We identified 673 genome-wide significant SNPs ($P_{random} < 5 \times 10^{-8}$) at 16 loci in European-ancestry populations (Fig. 1a, Table 1, Supplementary Tables 3 and 4; Online Methods for locus definition). No genome-wide significant risk loci were detected in African-ancestry, Japanese or Latino populations (Supplementary Fig. 2 and Supplementary Tables 5–7), possibly due to a lack of power. In the combined multi-ancestry meta-analysis, 205 additional SNPs were significant at $P_{random} < 5 \times 10^{-8}$, including 12 SNPs at two loci not detected in the European-ancestry analysis (Fig. 1b, Table 1, and Supplementary Tables 3 and 8). Altogether, 878 SNPs at 18 loci reached genome-wide significance, of which 69% were significant in both European-ancestry and multi-ancestry meta-analyses, 23% were significant in the multi-ancestry meta-analysis only, and 8% were significant in the European-ancestry meta-analysis only (Supplementary Tables 4 and 8 and Supplementary Fig. 3 for the regional plots of the 18 loci). All 18 loci remained genome-wide significant after further genomic control correction of the test statistics, confirming the robustness of these results (Supplementary Table 9).

The 18 chromosomal regions included five new loci associated with asthma at 5q31.3, 6p22.1, 6q15, 12q13.3, 17q21.33; two new associations at 6p21.33 and 10p14 that were independent from previously reported signals at these loci in ancestry-specific populations

(Latino⁶ and Japanese⁷, respectively); two associations at 8q21.13 and 16p13.13 that were previously reported for asthma plus hay fever but not for asthma alone in a study of European-ancestry populations⁸; and nine previously identified asthma loci.

None of the lead SNPs at the 18 loci showed evidence for heterogeneity in effect sizes across studies except for the lead variant at 9p24.1 (P_{het} for Cochran's Q test⁹=0.008 across European-ancestry studies and P_{het} =0.02 across multi-ancestry studies, Table 1, Supplementary Fig. 4). There was also significant evidence for heterogeneity in ancestry-specific effect sizes (P_{ethnic} =0.003) for the 6p22.1 lead SNP rs1233578, which, consequently, did not reach significance in the multi-ancestry analysis (Table 1, Supplementary Table 3). The meta-analysis of the pediatric subgroup showed evidence for association ($P_{\text{random}} = 5 \times 10^{-8}$) at five of the 18 loci (2q12, 5q31, 6p21.33 9p24.1 and 17q12–21) (Supplementary Figs. 5 and 6 and Supplementary Table 10). No loci specific to that group were identified.

The results provided genome-wide significant confirmation of nine previously reported loci in both European-ancestry and multi-ancestry meta-analyses (Table 1; Supplementary Figs. 3b and 4). Our results allow detailed analysis of the broad 17q12–21 locus. It is notable that the lead SNP (rs2952156) at this locus is within *ERBB2* ($P_{\text{random}}=2.2 \times 10^{-30}$ in multi-ancestry meta-analysis), at least 180 kb from the previously recognized asthma-associated signals at the *GSDMB/ORMDL3* haplotype block³ (Supplementary Fig. 7). This is attributable to effect size heterogeneity across studies (0.001 P_{het} 0.05) that extends over a 200 kb region that includes *ORMDL3* and *GSDMB* (Supplementary Table 11). This heterogeneity is partly due to age of asthma onset, as previously reported⁵. Indeed, in the pediatric group, the 17q12–21 SNPs did not show heterogeneity (P_{het} 0.09) and the lead SNP rs8069176 is 3.6 kb proximal to *GSDMB* ($P_{\text{random}}=P_{\text{fixed}}=4.4 \times 10^{-26}$), consistent with previous studies^{3,5}. The SNP effect sizes in the pediatric and non-pediatric studies show a significant difference for rs8069176 at the *GSDMB* locus ($P_{\text{het}}=7.4 \times 10^{-4}$) but no difference for rs2952156 at the *ERBB2* locus ($P_{\text{het}}=0.11$). These two SNPs are only in moderate LD ($r^2=0.30$) and, interestingly, each is in strong LD ($r^2>0.9$) with missense variants localized in *ERBB2* for the proxy of rs2952156 and in *ZBP2* and *GSDMB* for the proxies of rs8069176. Moreover, both rs2952156 and rs8069176 are associated with *GSDMB* and *ORMDL3* expression in blood e-QTL databases^{10–13} and with expression of *GSDMA*, *CDK12*, *GSDMB*, *ORMDL3* in whole lung tissue^{12,14}. However, only rs2952156 is associated with *PGAP3* transcript in lung^{12,14} (Supplementary Table 12a). Further exploration of eQTL data from GTEx¹² indicated that rs8069176 accounts for a large part of the association of the most significant SNP with *ORMDL3* transcript in blood while rs2952156 accounts for a large part of the association of the most significant SNP with *PGAP3* transcript in lung (Supplementary Table 12b), suggesting that the asthma-associated signals near *PGAP3/ERBB2* and *ORMDL3/GSDMB* blocks may affect asthma risk through the expression of different genes in different tissues..

Finally, of the 21 published asthma loci, 12 did not reach genome-wide significance in TAGC (Supplementary Table 13). The most significant SNPs in the GWAS catalog³ at seven of those loci had P-values>0.01 in TAGC analyses. Among these seven non-replicated loci, two (4q31.21⁷, 8q24.11¹⁵) were reported in Japanese, three (4q12, 9p23, 10q24.2)¹⁶ had

SNPs with low minor allele frequencies (< 2%) and were reported in a childhood-onset asthma study, and two (1q31.3¹⁷, 5q12.1¹⁸) were reported in European-ancestry children with asthma defined by current or persistent asthma symptoms with regular use of medication. The most significant SNPs at the remaining five loci had P-values $\leq 5 \times 10^{-4}$ in at least one TAGC meta-analysis, thus providing some replication. Amongst these five loci, the 1q23.1 locus is specific to African-ancestry populations¹⁹; the 12q13.2 SNP, reported by a Japanese study⁷, showed heterogeneity in the TAGC Japanese meta-analysis as well as in European-ancestry and multi-ancestry meta-analyses ($P_{\text{het}} = 0.05$); and the 7q22.3 SNP, reported in European-ancestry populations²⁰, was associated with a severe form of childhood asthma and also showed heterogeneity across studies in the original publication²⁰ (where the P_{random} value did not reach significance) as well as in our study (European-ancestry, multi-ancestry and pediatric meta-analyses, $0.006 \leq P_{\text{het}} \leq 0.03$). Finally, SNPs at 1q21.3 and 22q12.3 loci, previously reported in European-ancestry populations^{21,22}, did not show significant evidence for heterogeneity across TAGC studies in the European-ancestry and multi-ancestry meta-analyses ($0.11 \leq P_{\text{het}} \leq 0.19$). When we repeated these two meta-analyses, under a fixed-effects model and considering separately the set of TAGC datasets that were part of the original publication (set P) and the set of remaining TAGC datasets (set R), both 1q21.3 and 22q12.3 SNPs had higher effect sizes in set P than in set R. These differences in effect sizes did not reach significance for the 1q21.3 SNP (P_{het} for Cochran's Q test are 0.13 and 0.20 in European-ancestry and multi-ancestry analyses) and were borderline significant for the 22q12.3 SNP (0.04 $\leq P_{\text{het}} \leq 0.06$) (Supplementary Table 14). Altogether, these results suggest that the lack of replication is mainly due to heterogeneity that is attributable to various factors, such as ethnicity, specificity of clinical phenotypes or other factors as further discussed.

To investigate whether the 18 asthma loci identified in this study contain multiple distinct signals, we performed approximate conditional regression analysis based on summary statistics for all loci (Online Methods), except for the 9p24.1 region which showed heterogeneity in SNP effect size across studies over the whole locus. For the 17q12–21 locus, this analysis was restricted to the pediatric sub-group in which there was no heterogeneity. After conditioning on the lead SNP in each investigated region, four secondary signals (2q12, 5q22.1, 5q31, 6p21.32) remained significant ($P_{\text{fixed}} \leq 5 \times 10^{-8}$) (Supplementary Table 15), yielding 22 distinct genome-wide significant signals.

To provide biological insight into our findings, we conducted a comprehensive bioinformatic assessment of the asthma association signals. To pinpoint the most likely candidate genes at the nine loci harboring novel associations with asthma *per se*, we interrogated results of six eQTL studies in tissues relevant to asthma, blood (including peripheral blood^{11,12}, lymphoblastoid cell lines (LCLs)^{10,13}, monocytes²³) and whole lung tissue^{12,14}, and searched for missense variants potentially tagged by the association signals. To assess the level of overlap of asthma associations with susceptibility loci for other phenotypes, we interrogated the GWAS catalog³ while varying the strength of association with asthma (thresholds from 5×10^{-8} to 10^{-3}). To get greater insight into how asthma associated variants may functionally influence disease, we interrogated the ROADMAP/ENCODE functional genomics data generated in a wide range of human cell types²⁴. Finally, the degree of

connectivity between the asthma-associated loci was assessed through text mining²⁵. Results are described below.

Candidate genes at the nine loci showing novel associations

A summary of eQTL analysis for these nine loci is described in Table 2 and Supplementary Table 16; regional plots are shown in Supplementary Fig. 3a.

New asthma susceptibility loci—Five new loci were identified in this study. The strongest new signal in both the European-ancestry ($P_{\text{random}}=8.6\times 10^{-13}$) and multi-ancestry ($P_{\text{random}}=2.2\times 10^{-12}$) meta-analyses was with SNP rs2325291 in an intron of *BACH2* at 6q15, which is strongly correlated with rs10455168 ($r^2=0.91$), a cis-eQTL altering expression of *BACH2* in blood¹¹. *BACH2* encodes a zip transcription factor that regulates nucleic acid-triggered antiviral responses in human cells²⁶. The second strongest signal in the European-ancestry and multi-ancestry analyses was with rs17637472 ($P_{\text{random}}=3.3\times 10^{-9}$ and 6.6×10^{-9}), which lies between *ZNF652* and *PHB* at 17q21.33, and is a strong cis-eQTL for *GNGT2* (173 kb from rs17637472) in blood^{10,11,13,23}. *GNGT2* interacts with beta-arrestin 1 to promote G-protein-dependent Akt signaling for NF-kappaB activation²⁷.

Among the other new signals, the lead SNP rs1233578 at 6p22.1 ($P_{\text{random}}=5.3\times 10^{-9}$ in European-ancestry populations) resides between *TRIM27* and *GPX5*. This SNP was not associated with gene expression in blood or lung but is in LD ($r^2=0.6$ in European-ancestry populations) with rs7766356 (312 kb from rs1233578), which is a cis-eQTL for *ZSCAN12* in blood¹³ and *ZSCAN31* in lung¹⁴. These zinc finger protein encoding genes were associated with lung function²⁸. The two SNPs, rs1233578 and rs7766356, represent the same association signal in European-ancestry populations (the association with rs7766356 becomes non-significant after conditioning on the lead SNP rs1233578). The 12q13.3 lead SNP (rs167769), which was only significant in the multi-ancestry analysis ($P_{\text{random}}=3.9\times 10^{-9}$), lies in an intron of *STAT6* and is strongly associated with *STAT6* expression in blood^{10,11,13} and lung¹⁴. *STAT6* is a transcription factor, essential for the functional responses of Th2 lymphocytes mediated by IL-4 and IL-13²⁹. This result robustly establishes the association of *STAT6* with asthma risk that has been disputed by candidate gene studies³⁰. The 5q31.3 lead SNP rs7705042 ($P_{\text{random}}=7.9\times 10^{-9}$ in multi-ancestry analysis) is within an intron of *NDFIP1* and associated with *NDFIP1* expression in blood¹¹⁻¹³. *NDFIP1* is a potent inhibitor of antiviral response³¹ and inflammation processes³².

New asthma signals at loci reported in specific populations—Two associations in our study were with novel SNPs at loci previously reported to be associated with asthma in Latinos⁶ and Japanese⁷. The first one at 6p21.33 was reported in an admixture mapping study in Latinos⁶. The lead TAGC SNP, rs2855812 ($P_{\text{random}}=8.9\times 10^{-12}$ in the multi-ancestry analysis, $P_{\text{random}}=1.7\times 10^{-8}$ in the European-ancestry meta-analysis) lies in an intron of *MICB*. This SNP was not correlated ($r^2=0$) with any of the SNPs reported in the Latino study⁶. The 6p21.33 region harbors many genes whose transcripts are associated with TAGC asthma signals, including *TNF*, *LST1*, *HLA-C*, *LTA* in blood^{10,11,13} and *MICB* in lung^{12,14}. These genes are involved in immune-related mechanisms. This 6p21.33 locus is about 600

kb apart from the previously reported 6p21.32 locus that spans HLA-Class II genes. Intensive sequencing efforts will be needed to further clarify the HLA region associations. The second association was at 10p14 locus where a GWAS in Japanese⁷ reported association (lead SNP rs10508372) with adult asthma. We detected a new signal, rs2589561, in European-ancestry ($P_{\text{random}}=1.4\times 10^{-8}$) and multi-ancestry meta-analyses ($P_{\text{random}}=3.5\times 10^{-9}$), that is not correlated with rs10508372 in either European-ancestry or Japanese populations. The SNP rs2589561 is in a gene desert, 929 kb distal of *GATA3*. However, recently published promoter capture Hi-C data in hematopoietic cells³³ revealed that two proxies of rs2589561 ($r^2>0.9$) lie in a region that interacts with the *GATA3* promoter, especially in CD4+T cells. This suggests that the SNP may be in a distal regulator of *GATA3*, which encodes a transcription factor that is a master regulator of differentiation of Th2 cells and innate lymphoid cells type 2³⁴.

Asthma signals reported for asthma plus hay fever—Loci on chromosomes 8q21.13 and 16p13.13 were previously associated with asthma plus hay fever but not with asthma alone in one European-ancestry study⁸. In our results, the 8q21.13 lead SNP rs12543811 ($P_{\text{random}}=3.4\times 10^{-8}$ and 1.1×10^{-10} in the European-ancestry and multi-ancestry analyses) lies between *TPD52* and *ZBTB10* and is in strong LD ($r^2=0.79$) with the previously reported asthma/hay fever SNP rs7009110. These two SNPs represent the same signal, as the association with rs12543811 becomes non-significant after conditioning on rs7009110. Thus, the 8q21.13 locus is likely implicated in allergic asthma. A functional analysis of the asthma/hay fever locus pinpointed *PAG1* as a promising candidate³⁵. The chromosome 16p13.13 SNP rs17806299 is within an intron of *CLEC16A* ($P_{\text{random}}=2.1\times 10^{-10}$ and 2.7×10^{-10} in European-ancestry and multi-ancestry meta-analyses). Although in moderate LD ($r^2=0.66$) with the previously reported asthma/hay fever signal (rs62026376)⁸, the association of asthma with rs17806299 was removed after conditioning on rs12935657 ($r^2=0.96$ with rs62026376), indicating that these SNPs represent the same signal and 16p13.13 is probably also an allergic asthma locus. The SNP rs17806299 is strongly associated with the expression of a nearby gene, *DEXI* in blood^{11,23}. Similar observations of associations of *CLEC16A* SNPs with autoimmune diseases and expression of *DEXI* together with chromosome conformation capture experiments implicated *DEXI* as the most likely candidate gene for autoimmune diseases³⁶. The potential relevance of *DEXI* in allergic diseases has also been previously discussed⁸.

It is notable that the lead SNPs at the nine new asthma-associated loci lie in non-coding regions and are not tagging missense variants.

Overlap of loci associated with asthma and other phenotypes

We next explored whether the nine loci that harbored new signals for asthma *per se* overlapped with GWAS loci reported for allergy-related phenotypes, lung function phenotypes, or other immune-related diseases using the GWAS catalog³. Six of these nine asthma loci showed overlapping associations with allergy-related phenotypes and eight of them with auto-immune diseases or infection-related phenotypes (Table 2). Moreover, three asthma loci overlapped with associations with lung function phenotypes.

We expanded our search of overlap between the asthma association signals having multi-ancestry $P_{\text{random}} < 10^{-4}$ in this study and GWAS signals with all phenotypes and diseases in the GWAS catalog³. We examined 4,231 unique trait-loci combinations (Online Methods), and used the disease classification from Wang *et al.*³⁷ to group traits. We summarized the overlap with GWAS catalog signals as the proportion of catalog SNPs having asthma P -values $< 10^{-4}$ in our analysis. This revealed significant overlap with autoimmune disease (10%, i.e. 49 out of 480 catalog SNPs show evidence for asthma association), consistent with the hypothesized shared susceptibility^{38,39}, moderate overlap with diseases having an inflammatory component (cardiovascular diseases, cancers, neuro-psychiatric diseases), and small to no overlap with other diseases (Table 3). When investigating specific diseases and traits (Supplementary Table 17), the most significant overlap is with allergic phenotypes. There is little to no overlap with other phenotypes that appear most frequent in the GWAS catalog (for example, no shared associations with type 2 diabetes).

When we broadened our analysis to a larger set of SNPs in the GWAS catalog to identify loci for diseases with potentially shared genetic architecture with asthma (i.e, SNPs associated with asthma at $P_{\text{random}} = 10^{-3}$ in our multi-ancestry meta-analysis), additional pleiotropic signals emerged (Supplementary Table 18). This larger set of associations suggests a broader picture of asthma risk, with a wide range of pleiotropic effects for traits ranging from lung cancer and multiple sclerosis (with rs3817963 in *BTNL2*) to coronary heart disease (with rs1333042 near *CDKN2B*). This analysis also generated an extended set of asthma candidate genes. Indeed, there are 210 SNPs in the GWAS catalog that are associated with asthma in TAGC at a threshold of 10^{-3} ; the proportion of false positives among these is smaller than 1%.

Enrichment of asthma risk loci in epigenetic marks

Because nearly all lead SNPs at the 18 loci identified by this study lie in non-coding sequences, except for the *IL13* missense variant (rs20541), we investigated whether the asthma-associated variants and their proxies ($r^2 = 0.80$) were concentrated in cis-regulatory DNA elements. Only 16 of 18 identified asthma loci were explored because we excluded the two loci spanning the HLA region due to the large amount of variability and extensive LD in this region. We interrogated the 111 ROADMAP and 16 ENCODE reference epigenomes in a wide range of human cell types²⁴. We focused on histone marks characterizing enhancers and promoters assayed in all 127 epigenomes and DNase I-hypersensitive sites available in 51 cell types. To assess enrichment of the asthma risk variants for co-localization with these regulatory elements, we used the Uncovering Enrichment through Simulation pipeline⁴⁰. This approach generates random SNP sets that match the characteristics of the original asthma-associated SNPs (distance from the nearest transcription start site, number of LD partners, minor allele frequency). Empirical P-values for enrichment are calculated by comparing the observed frequency of co-localization of SNPs with a given type of regulatory element in the original asthma-associated SNP set to the co-localization frequency distribution obtained from the 10,000 random SNP sets generated. Benjamini-Hochberg false discovery rates (FDRs) are then computed to correct for multiple testing (Online Methods).

While the asthma-associated variants were strongly enriched for co-localization with enhancer marks, there was only weak enrichment in promoter marks (Table 4 and Supplementary Table 19). This enrichment was highest in leukocytes (27 leukocytes of which 19 (70%) are lymphocytes and monocytes). For example, a FDR 5% for enrichment of asthma loci in active enhancers was observed in 100% of leukocytes compared to 50% of all cell types. The enrichment of asthma risk variants for co-localization with DNase I-hypersensitive sites was intermediate between the enrichments in promoters and enhancers and was again increased in blood cells (FDR 5% in 40% of leukocytes and 12% of all cell types) (Table 4 and Supplementary Table 20).

The strong enrichment of asthma loci in enhancer marks, especially in immune cells, indicates that the associated genetic variants are likely involved in regulation of immune-related functions. This also suggests that epigenetic mechanisms may be key to promoting asthma, as evidenced for IgE levels, an asthma-associated phenotype⁴¹.

Connectivity between asthma-associated loci

To characterize the degree of connectivity between the 18 asthma-associated loci, we applied the Gene Relationships Across Implicated Loci (GRAIL) text-mining approach²⁵. Genes at eleven of these loci showed connections with a GRAIL score, P_{GRAIL} , less than 5% (7 of them being highly connected with $P_{\text{GRAIL}} < 10^{-3}$) (Fig. 2 and Supplementary Table 21). These genes were connected by keywords such as ‘asthma’, ‘allergy’, ‘atopic’, ‘interleukin’, ‘cytokines’, ‘airway’, and ‘inflammation’, confirming the central role of immune-related mechanisms accounting for these connections.

DISCUSSION

In this meta-analysis of worldwide asthma GWAS in ethnically-diverse subjects, we discovered nine novel loci influencing asthma risk. This study confirms that immune-related mechanisms are prominent in asthma susceptibility and brings novel insights that open new routes for future asthma research. The asthma-associated loci identified by TAGC are enriched in enhancer marks and are likely to be involved in gene regulation. Although this was observed in immune cells, asthma genes (e.g., *IL1RL1*, *TSLP*, *IL33*, *ORMDL3/GSDMB*) are also expressed in the airway epithelium where they modulate airway inflammation. Investigation of epigenetic marks in airway epithelial cells may bring additional insight. The best candidates at many loci are involved in immune response to viruses or bacteria, which underlines the importance of infections in asthma risk. This study further provides evidence for overlap of asthma loci with loci underlying auto-immune diseases and other diseases that have an inflammatory component, which strengthens the growing importance of pleiotropy in multifactorial diseases.

Our meta-analysis doubles the number of cases from prior genome-wide studies at the time of analysis^{21,22}. We identified 878 SNPs that correspond to 22 distinct association signals at 18 loci meeting criteria for genome-wide significance in European-ancestry and/or multi-ancestry populations. Pooling data from ethnically-diverse populations can increase power to detect new loci (two loci reached the genome-wide threshold only in the multi-ancestry analysis) but may also increase heterogeneity. Besides differences in the genetic background,

varying environmental exposures can modify genetic risks and result in heterogeneity in SNP effect size, and consequently reduce power of multi-ancestry analysis compared to ancestry-specific analysis. Assuming an asthma prevalence of 10%, the variance in liability to asthma explained by the 22 genome-wide significant variants of this study was estimated to be 3.5% (95% Confidence Interval : 2.0%–5.4%) of which 72% was accounted for by the known loci and 28% by the new loci. It is of note that the current study was based on HapMap2-imputed data which was shared within the TAGC consortium and thus allowed detection of associations with common genetic variants (MAF \geq 1%).

The overall relative paucity of asthma risk loci detected by large-scale GWAS compared to other common diseases may be due to the clinical heterogeneity of asthma and the important role of differing environmental exposures. It is recognized that asthma is not a single disease but that the syndrome varies based on many characteristics⁴², including age of asthma onset, the severity of disease, the type of cellular inflammatory infiltrates, occupational exposures and the varying response to treatment.. It is thus possible that additional asthma loci will be revealed by studies targeting more specific asthma sub-phenotypes and/or taking into account environmental exposures.

In conclusion, future discoveries might come by exploring more complex models of asthma phenotypes and through the joint analysis of asthma and other immune-mediated and inflammatory diseases. The central role of gene regulatory mechanisms highlighted by our study might prompt genome-wide explorations of the epigenome in immune cells and the respiratory epithelium while integrating information on genetic variation and environmental exposure histories.

ONLINE METHODS

GWAS Studies and Data Shared

All 66 genome-wide association studies that form the TAGC consortium are described in the Supplementary Note and summarized in Supplementary Table 1. These studies included 56 studies of European-ancestry (19,954 cases, 107,715 controls), seven studies of African-ancestry (2,149 cases, 6,055 controls), two Japanese studies (1,239 cases, 3,976 controls) and one Latino study (606 cases, 792 controls), making a total of 23,948 cases and 118,538 controls. There were 27 studies including only childhood-onset asthma (defined as asthma diagnosed at or before 16 years of age) which allowed us analyzing separately a pediatric subgroup (8,976 cases, 18,399 controls). All subjects provided informed consent to participate in genetic studies and local ethics committees for each of the individual studies approved the study protocol. Definition of asthma was based on doctor's diagnosis and/or standardized questionnaires (see Supplementary Note for details). The samples were genotyped on a variety of commercial arrays, detailed in the Supplementary Note and Supplementary Table 2. GWAS were performed on imputed SNP data that were generated using HapMap2 as reference panel and one of the commonly used imputation software (Supplementary Note and Supplementary Table 2). In each dataset, the effect of each individual SNP on asthma, assuming an additive genetic model, was estimated through a logistic regression-based approach and expressed in terms of a regression coefficient with its

standard error; the detailed methodology and software used for analysis by each study can be found in the Supplementary Note and Supplementary Table 2.

Imputation, quality control (including adjustments for population stratification) and analysis was done by each group independently and data on a predefined set of 3,952,683 autosomal SNPs was shared. These SNPs were those of the HapMap Phase 2, release 21 panel in subjects from European, Asian and African-ancestry that were filtered using SNP annotation from the build 37.3 of the reference sequence and dbSNP b135 (31,587 SNPs (0.8% of all SNPs) from previous annotations that showed discrepancies with the chosen annotation were deleted). The variables that were shared contained the study name, general information on SNPs (rs number, chromosome, position, alleles (baseline and effect alleles as used in the analysis by each study), SNP status (imputed or genotyped SNP and whether the SNP genotype or imputed value was used in computation), quality control (QC) indicators (call rate and P -value for Hardy-Weinberg (HW) equilibrium test for genotyped SNPs, software used for imputation and imputation quality score for imputed SNPs), allele frequencies in cases and controls and information on association statistics (regression coefficient for SNP effect, standard error of regression coefficient, Z scores, P -values associated with Z score statistic).

Quality control of shared data

For each SNP, the alleles on the HapMap2 template (reference and alternate alleles on the positive strand) were compared to the alleles (baseline and effect alleles) used in the analysis by each group. When necessary, the association variables (allele frequencies, regression coefficient for SNP effect, Z score) were swapped to match the reference/alternate alleles of the template. Data for each SNP showing any ambiguity or error in assignment to the template were set to missing. In addition, a number of QC checks were done regarding the name, format, range of possible values for all shared variables mentioned in the previous paragraph as well as consistency checks across variables. Any problem or inconsistency was corrected, otherwise the data for that SNP were set to missing. After this first stage of QC procedure, association statistics for at least one SNP in at least one study were available for 2.83 million autosomal SNPs. Strict QC criteria were used for inclusion of a SNP in the analysis. When a SNP genotype was used in the study analysis, these criteria were: call rate 99%, P -value for HW test 10^{-6} and minor allele frequency (MAF) 0.01 in both controls and cases. When a SNP imputed value was used in the analysis, the criteria were: imputation quality score 0.5 and MAF 0.01 in both controls and cases. The distribution of the summary statistics (regression coefficient for SNP effect, standard error, Z score) of all SNPs passing QC was examined for each study; SNPs that still showed extreme Z scores (7 or -7) after QC were excluded.

Meta-analysis of asthma GWAS

We conducted fixed-effects meta-analysis with inverse variance weighting and random-effects meta-analysis using the Der Simonian and Laird⁴³ estimator of the between-study variance when the meta-analyses included a large number of studies (European-ancestry, multi-ancestry and pediatric sub-group meta-analyses), which allows an accurate estimate of the between-study variance. We used a fixed-effects model for the meta-analyses of the

African-ancestry, Japanese and Latino populations.. For all these meta-analyses, we used the SNP regression coefficient and standard error from each study for which the SNP passed QC. All meta-analyses were done with Stata version 14.1 (Stata Corp., College Station, Texas, USA). To minimize the false-positive findings and to obtain robust results, we examined the combined results for SNPs for which at least two-thirds of the studies contributed to a meta-analysis. Tests of significance of the combined effect sizes were performed using a standard normal distribution. We applied a threshold of P_{random} (or P_{fixed}) of 5×10^{-8} to declare a combined SNP effect as genome-wide significant. To verify the robustness of the results, we applied a genomic control correction to the association test statistics. The lead SNP at a locus was the variant with the strongest evidence for association in the European-ancestry or multi-ancestry meta-analysis. We defined a support interval around the lead SNP designated as “locus”; the bounds of this interval were the positions of the two most extreme SNPs among all SNPs lying within 500 kb on each side of the lead SNP and having P_{random} (or P_{fixed}) 10^{-6} . Heterogeneity of per-SNP effect sizes across all studies in a meta-analysis was assessed using the Cochran’s Q test⁹. A difference between the four ethnic-specific summary effects was also tested with the Cochran’s Q statistic.

Conditional analysis of asthma-associated loci

The Genome-wide Complex Trait Analysis (GCTA) software⁴⁴ (see URLs) was used to perform approximate conditional analysis for all loci with at least one SNP reaching the genome-wide significance level. This approximate conditional analysis is based on the summary meta-analysis statistics obtained under a fixed-effects model and takes into account the correlations among SNPs, that are estimated from a large reference population included in the meta-analysis. Approximate conditional analysis was only carried out in the European-ancestry ethnic group which can be assumed to share a similar LD pattern and represents the largest ancestry-specific dataset and the only one to show genome-wide significant results. As this analysis assumes no heterogeneity in SNP effect size across studies, the 9p24.1 and 17q12–21 loci, that show significant heterogeneity ($P_{\text{het}} < 0.05$ based on the Cochran’s Q test) for a large portion of each locus, were not investigated. However, for the 17q12–21 locus, where there is no heterogeneity in the pediatric sub-group, GCTA was restricted to the European-ancestry pediatric sub-group. We used the large ECRHS (European Community Respiratory Health Survey) dataset as the reference sample to estimate LD. This dataset was genotyped using Illumina Human610Quad array and included 2,101 unrelated individuals after QC²². Imputation was done using the MACH software⁴⁵ and HapMap2, release 21 panel; only well-imputed SNPs (imputation quality score $\text{rsq} > 0.8$) and with minor allele frequency (MAF) $\geq 1\%$ were kept in this reference panel. For each asthma-associated locus, the region explored by conditional analysis extended by 500 kb on each side of the two extreme SNPs defining the support interval around the lead SNP (see preceding paragraph). However, we reduced that extension to 250 kb for the 6p21.33 and 6p21.32 loci to avoid overlap. The length of the regions explored by conditional analysis varied from 1.01 Mb to 1.63 Mb. Within each investigated region by conditional analysis, fixed-effects summary meta-analysis data for SNPs belonging to that region were adjusted for the lead SNP using the `--cojo-cond` option; tests for the adjusted SNP effects were based on the Wald test. If there was an additional SNP meeting the Bonferroni-corrected threshold for the total number of SNPs overall all regions investigated by GCTA ($P = 4.1 \times 10^{-6}$) after

adjustment for the lead SNP, we performed an additional round including both SNPs. If the remaining SNPs had P -values greater than 4.1×10^{-6} , no further analysis was performed. The results of this analysis are reported in Supplementary Table 15.

Identification of cis-eQTLs at new asthma risk loci

To get greater insight into the potential genes driving the association signals at the novel asthma loci, we defined a list of SNPs to be interrogated that included the lead SNPs, the secondary signals identified by conditional analysis and all SNPs in LD with these SNPs (r^2 comprised between 0.5 and 1). To search for cis-expression quantitative trait loci (eQTLs) within at most 1 Mb of each investigated SNP, we interrogated six publically available eQTL databases by giving priority to cell types more likely to be involved in asthma biology (blood cell types and lung tissue): (i) a meta-analysis of the transcriptional profiles from peripheral blood cells of 5,311 European-ancestry subjects (the blood eQTL browser¹¹); (ii) the gene expression data of 777 lymphoblastoid cell lines (LCLs) from the MuTHER database¹⁰; (iii) the transcription profiles of 405 and 550 lymphoblastoid cell lines from UK asthma (MRCA) and eczema (MRCE) family members, respectively¹³; (iv) the eQTL data from monocytes of 1,490 subjects included in the GH-express database²³; (v) the GTEx eQTL Browser with data from multiple tissues including blood and lung¹²; (vi) the transcriptional profiles from lung tissues of 1,111 subjects¹⁴ (see URLs).

Search for missense variants at new asthma risk loci

To complement the eQTL analysis, we searched whether the lead asthma-associated SNPs and secondary signals were in LD ($r^2 > 0.5$) with missense variants using the HaploReg v4.1 tool (see URLs).

Overlap of loci associated with asthma and other phenotypes

Overlap of novel asthma risk loci with associations with allergy-related phenotypes/diseases and immune-related diseases as well as lung function phenotypes was first annotated using the March 24, 2015 version of the NHGRI-EBI (National Human Genome Research Institute and European Bioinformatics Institute) GWAS catalog³ (see URLs) We then used this catalog to systematically investigate the overlap of asthma signals having $P_{\text{random}} = 10^{-4}$ in the multi-ancestry meta-analysis with association signals of all diseases and traits in the catalog. That version of the catalog had 19,080 SNP entries, and 16,047 of those SNPs had a TAGC asthma association P -value. To investigate pleiotropy, we filtered out SNPs associated with asthma in the database, SNPs that have a reported GWAS P -value larger than 10^{-7} (with the intent of removing some of the potential false positives in the catalog) and SNPs that are duplicated (i.e., remove disease-SNP duplications). This reduced the number of entries to 5,927. Note that this process did not remove SNPs in perfect LD associated with the same disease, nor SNPs that were present multiple times in the database as associated with different phenotypes. For some diseases or quantitative traits, there were multiple SNPs in the same region reported in the catalog potentially yielding redundant information. Some of the SNPs could be in strong LD, but some could reflect independent signals. To avoid possible duplication of signals, we decided to keep only unique trait-loci combinations as reflected by the variables "Disease.Trait" and "Region" in the catalog. There were 4,231 unique entries left after this filtering step. Diseases/traits in the GWAS catalog were grouped

using the classification from Wang *et al.*³⁷ We summarized the overlap of GWAS catalog signals with asthma signals by the proportion of catalog SNPs with asthma P -values smaller than 10^{-4} in our analysis. The significance of overlap was estimated by the binomial tail probability for observing the number of TAGC SNPs with $P_{\text{random}} < 10^{-4}$ among the number of SNPs reported in the GWAS catalog for a group of diseases. The significance threshold for enrichment in shared associations between a disease group and asthma was set equal to 0.05 divided by the number of disease groups investigated using a Bonferroni correction. Finally, we examined a larger set of SNPs in the GWAS catalog that show an association with asthma at $P_{\text{random}} < 10^{-3}$ in TAGC multi-ancestry meta-analysis and estimated the proportion of false positives among those SNPs.

Enrichment of asthma risk loci in epigenetic marks

To get greater insight into the functional role of the genetic variants at the novel and known asthma loci identified by this study, we investigated whether the lead SNPs and their proxies ($r^2 > 0.80$) were concentrated in cis-regulatory DNA elements. We used the Uncovering Enrichment through Simulation pipeline⁴⁰ (see URLs) that was adapted to the current study. This approach tests if GWAS-identified SNPs are enriched in particular functional annotations through use of Monte Carlo simulations. The original set of asthma-associated SNPs included the lead SNPs at each asthma risk locus (ie one SNP per asthma-associated locus, as recommended by Hayes *et al.*⁴⁰). We excluded the two associated loci that span the HLA region (6p21.33 and 6p21.32) because of the high amount of variability and LD in this region. Each of the original lead SNPs is categorized by its distance from the nearest transcription start site (TSS) and number of LD partners ($r^2 > 0.8$). Quartiles for both the TSS distance and LD partner count are calculated and the initial SNPs are binned accordingly. Then, SNPs from the whole set of imputed SNPs used for analysis are binned according to the original SNP criteria (distance from the closest TSS, number of LD partners, and also MAF). Random SNP sets are chosen, matching to the original bin frequencies. LD partners ($r^2 > 0.8$) for both the original lead SNPs and random SNPs are retrieved. The SNP data, including the original and random sets of SNPs and their corresponding LD partners ($r^2 > 0.8$), are intersected with the cell-specific epigenome tracks of regulatory elements using the BedTool's intersectBed⁴⁶, to determine which SNPs co-localize with a given type of regulatory elements (for example, enhancers or promoters). Those resultant SNPs are then collapsed into loci that co-localize with marks based on LD structure. We computed an empirical- P value for a specific track using 10,000 random SNP sets (this P -value is equal to r_{loci}/n where r_{loci} is the number of instances when the frequency of co-localization of the random SNP sets with the regulatory feature is greater than or equal to the frequency of co-localization with the feature for the original SNP set and n is the number of random SNP sets generated (here, 10,000). We used the Benjamini-Hochberg false discovery rates (FDR) to correct for multiple testing. We interrogated the functional data from 111 ROADMAP reference epigenomes and 16 additional epigenomes from ENCODE (Encyclopedia of DNA elements) that are available in a wide range of human cell and tissue types²⁴ (see URLs). We focused on enhancers and promoters that were defined using the ChromHMM 15-state model assayed in all 127 epigenomes. We also examined enrichment in DNase I hypersensitivity sites that are available in 51 cell types.

Connectivity between asthma-associated loci

We used GRAIL (Gene Relationships Across Implicated Loci)²⁵ to assess the relatedness between asthma associated loci. As described in detail previously²⁵, to define the genes near each SNP, GRAIL finds the furthest neighboring SNPs in the 3' and 5' direction that are in LD ($r^2 > 0.5$) and proceeds outward in each direction to the nearest recombination hotspot. All genes that overlap that interval are considered implicated by the SNP. If there are no genes in that region, the interval is extended by 250 kb in either direction. We took the genome-wide significant signals identified by this study as a seed and queried loci to investigate biological connectivity among those loci. The connectivity between genes belonging to these loci was assessed through text-mining of PubMed abstracts. Each gene at each locus was scored for enrichment in GRAIL connectivity to genes located at the other loci by using statistical text-mining methods, as previously described²⁵. The interconnectivity among genes at asthma risk loci was visualized using VIZGRAIL⁴⁷ (see URLs).

Variance explained by the asthma associated genetic variants

We estimated the variance in liability to asthma explained by the 22 distinct genome-wide significant SNPs (18 lead SNPs plus four secondary signals identified by approximate conditional analysis) at the 18 asthma-associated loci using a method based on the liability threshold model⁴⁸ and assuming a prevalence of asthma of 10%. The variance in liability to asthma explained by individual SNPs was summed over all 22 significant variants. For the loci that included two SNPs (lead SNP and secondary signal), we used the SNP effect sizes estimated by approximate joint analysis using GCTA⁴⁴. We also estimated the variance in liability to asthma explained by the nine lead SNPs at the nine new asthma loci and by the 13 distinct genome-wide significant signals at the nine known loci.

Data availability statement

The summary statistics of the meta-analysis that support the findings of this study are available through a link from the GWAS Catalog entry for the TAGC study on the EMBL-EBI (European Bioinformatics Institute) web site (<https://www.ebi.ac.uk/gwas/downloads/summary-statistics>).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Florence Demenais^{1,2,*}, Patricia Margaritte-Jeannin^{1,2,*}, Kathleen C Barnes^{3,*}, William OC Cookson^{4,*}, Janine Altmüller⁵, Wei Ang⁶, R Graham Barr⁷, Terri H Beaty⁸, Allan B Becker⁹, John Beilby¹⁰, Hans Bisgaard¹¹, Unnur Steina Bjornsdottir¹², Eugene Bleecker¹³, Klaus Bønnelykke¹¹, Dorret I Boomsma¹⁴, Emmanuelle Bouzigon^{1,2}, Christopher E Brightling¹⁵, Myriam Brossard^{1,2}, Guy G Brusselle^{16,17,18}, Esteban Burchard¹⁹, Kristin M Burkart²⁰, Andrew Bush^{21,22}, Moira Chan-Yeung²³, Kian Fan Chung^{21,24}, Alexessander Couto Alves²⁵, John A Curtin²⁶,

Adnan Custovic²⁷, Denise Daley^{23,28}, Johan C de Jongste²⁹, Blanca E Del-Rio-Navarro³⁰, Kathleen M Donohue⁷, Liesbeth Duijts³¹, Celeste Eng³², Johan G Eriksson³³, Martin Farrall^{34,35}, Yuliya Fedorova³⁶, Bjarke Feenstra³⁷, Manuel A Ferreira³⁸, Australian Asthma Genetics Consortium collaborators, Maxim B Freidin³⁹, Zofia Gajdos^{40,41}, Jim Gauderman⁴², Ulrike Gehring⁴³, Frank Geller³⁷, Jon Genuneit⁴⁴, Sina A Gharib⁴⁵, Frank Gilliland⁴², Raquel Granell^{46,47}, Penelope E Graves⁴⁸, Daniel F Gudbjartsson^{49,50}, Tari Haahtela⁵¹, Susan R Heckbert⁵², Dick Heederik⁵³, Joachim Heinrich^{54,55}, Markku Heliövaara⁵⁶, John Henderson^{46,47}, Blanca E Himes⁵⁷, Hiroshi Hirose⁵⁸, Joel N Hirschhorn^{41,59,60}, Albert Hofman^{17,61}, Patrick Holt⁶², Jouke Jan Hottenga¹⁴, Thomas J Hudson^{63,64}, Jennie Hui^{10,65,66}, Medea Imboden^{67,68}, Vladimir Ivanov⁶⁹, Vincent WV Jaddoe⁷⁰, Alan James^{71,72}, Christer Janson⁷³, Marjo-Riitta Jarvelin^{74,75,76,77}, Deborah Jarvis^{21,78}, Graham Jones⁷⁹, Ingileif Jonsdottir^{49,80}, Pekka Jousilahti⁵⁶, Michael Kabesch⁸¹, Mika Kähönen⁸², David B Kantor^{83,84}, Alexandra S Karunas^{36,85}, Elza Khusnutdinova^{36,85}, Gerard H Koppelman^{86,87}, Anita L Kozyrskyj⁸⁸, Eskil Kreiner¹¹, Michiaki Kubo⁸⁹, Rajesh Kumar^{90,91}, Ashish Kumar^{67,68,92}, Mikko Kuokkanen^{56,93}, Lies Lahousse^{17,94}, Tarja Laitinen⁹⁵, Catherine Laprise^{96,97}, Mark Lathrop⁹⁸, Susanne Lau⁹⁹, Young-Ae Lee^{100,101}, Terho Lehtimäki¹⁰², Sébastien Letort^{1,2}, Albert M Levin¹⁰³, Guo Li⁴⁵, Liming Liang^{61,104}, Laura R Loehr¹⁰⁵, Stephanie J London¹⁰⁶, Daan W Loth¹⁷, Ani Manichaikul¹⁰⁷, Ingo Marenholz^{100,101}, Fernando J Martinez⁴⁸, Melanie C Matheson¹⁰⁸, Rasika A Mathias¹⁰⁹, Kenji Matsumoto¹¹⁰, Hamdi Mbarek¹⁴, Wendy L McArdle¹¹¹, Mads Melbye^{37,112,113}, Erik Melén^{92,114,115}, Deborah Meyers¹³, Sven Michel⁸¹, Hamida Mohamdi^{1,2}, Arthur W Musk^{116,117}, Rachel A Myers¹¹⁸, Maartje AE Nieuwenhuis^{87,119}, Emiko Noguchi¹²⁰, George T O'Connor^{121,122}, Ludmila M Ogorodova¹²³, Cameron D Palmer^{41,59}, Aarno Palotie^{93,124,125}, Julie E Park²³, Craig E Pennell⁶, Göran Pershagen^{92,114}, Alexey Polonikov⁶⁹, Dirkje S Postma^{87,119}, Nicole Probst-Hensch^{67,68}, Valery P Puzyrev³⁹, Benjamin A Raby¹²⁶, Olli T Raitakari¹²⁷, Adaikalavan Ramasamy^{25,128}, Stephen S Rich¹⁰⁷, Colin F Robertson¹²⁹, Isabelle Romieu^{130,131}, Muhammad T Salam^{42,132}, Veikko Salomaa⁵⁶, Vivi Schlünssen¹³³, Robert Scott¹³⁴, Polina A Selivanova¹³⁵, Torben Sigsgaard¹³³, Angela Simpson^{26,136}, Valérie Siroux^{137,138}, Lewis J Smith¹³⁹, Maria Solodilova⁶⁹, Marie Standl⁵⁵, Kari Stefansson^{49,80}, David P Strachan¹⁴⁰, Bruno H Stricker^{17,141,142}, Atsushi Takahashi⁸⁹, Philip J Thompson¹⁴³, Gudmar Thorleifsson⁴⁹, Unnur Thorsteinsdottir^{49,80}, Carla MT Tiesler^{55,144}, Dara G Torgerson³², Tatsuhiko Tsunoda^{89,145}, André G Uitterlinden¹⁴², Ralf JP van der Valk¹⁴⁶, Amaury Vaysse^{1,2}, Sailaja Vedantam^{40,41}, Andrea Von Berg¹⁴⁷, Erika Von Mutius^{148,149}, Judith M Vonk^{87,150}, Johannes Waage¹¹, Nick J Wareham¹³⁴, Scott T Weiss¹²⁶, Wendy B White¹⁵¹, Magnus Wickman^{92,152}, Elisabeth Widén⁹³, Gonneke Willemsen¹⁴, L Keoki Williams^{153,154}, Inge M Wouters⁵³, James J Yang¹⁵⁵, Jing Hua Zhao¹³⁴, Miriam F Moffatt^{4,*}, Carole Ober^{156,*}, and Dan L Nicolae^{157,*}

Affiliations

¹Genetic Variation and Human Diseases Unit, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France ²Institut Universitaire d'Hématologie, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France ³Division of

Biomedical Informatics and Personalized Medicine, Colorado Center for Personalized Medicine, University of Colorado, Denver, Colorado, USA ⁴Section of Genomic Medicine, National Heart and Lung Institute, London, UK ⁵Cologne Center for Genomics and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany ⁶School of Women's and Infants' Health, The University of Western Australia, Perth, Western Australia, Australia ⁷Departments of Medicine and Epidemiology, Columbia University, New York, New York, USA ⁸Division of Genetic Epidemiology, Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA ⁹Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada ¹⁰Department of the Diagnostic Genomics Laboratory, PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia ¹¹Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark ¹²Department of Medicine, Landspítali, The National University Hospital of Iceland, Reykjavik, Iceland ¹³Center for Genomics, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA ¹⁴Department of Biological Psychology, Amsterdam Public Health research institute, Vrije Universiteit, Amsterdam, The Netherlands ¹⁵University of Leicester, Institute for Lung Health, Glenfield Hospital, Leicester, UK ¹⁶Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium ¹⁷Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands ¹⁸Department of Respiratory Medicine, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands ¹⁹Department of Bioengineering & Therapeutic Sciences and Medicine, University of California, San Francisco, California, USA ²⁰Division of Pulmonary, Allergy and Critical Care, College of Physicians and Surgeons, Columbia University, New York, New York, USA ²¹National Heart and Lung Institute, Imperial College, London, UK ²²Royal Brompton Harefield National Health Service (NHS) Foundation Trust, London, UK ²³Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada ²⁴Biomedical Research Unit, Royal Brompton & Harefield National Health Service (NHS) Trust, London, UK ²⁵Department of Epidemiology and Biostatistics, Imperial College London, London, UK ²⁶Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK ²⁷Department of Paediatrics, Imperial College London, London, UK ²⁸Centre for Heart and Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada ²⁹Department of Pediatrics - Division of Respiratory Medicine, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands ³⁰Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico ³¹Department of Pediatrics-Division of Respiratory Medicine and Department of Pediatrics-Division of Neonatology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands ³²Department of Medicine, University of California, San Francisco, California, USA ³³Department of General Practice and Primary Health Care, University of Helsinki and Helsinki

University Hospital, Helsinki, Finland ³⁴Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK ³⁵Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK ³⁶Institute of Biochemistry and Genetics, Ufa Scientific Center of Russian Academy of Sciences, Ufa, Russian Federation ³⁷Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark ³⁸Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia ³⁹Population Genetics Laboratory, Research Institute of Medical Genetics, Tomsk NRMС, Tomsk, Russian Federation ⁴⁰Divisions of Genetics and Endocrinology, Children's Hospital, Boston, Massachusetts, USA ⁴¹Broad Institute, Cambridge, Massachusetts, USA ⁴²Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA ⁴³Division Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands ⁴⁴Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany ⁴⁵Department of Medicine, University of Washington, Seattle, Washington, USA ⁴⁶Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK ⁴⁷MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK ⁴⁸Asthma and Airway Disease Research Center and BIO5 Institute, The University of Arizona, Tucson, Arizona, USA ⁴⁹deCODE genetics, Amgen Inc., Reykjavik, Iceland ⁵⁰School of Engineering and Natural Sciences, Univeristy of Iceland, Reykjavik, Iceland ⁵¹Skin and Allergy Hospital, University of Helsinki, Helsinki, Finland ⁵²Department of Epidemiology, University of Washington, Seattle, Washington, USA ⁵³Division Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands ⁵⁴Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital in Munich, Munich, Germany ⁵⁵Institute of Epidemiology I, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany ⁵⁶National Institute for Health and Welfare (THL), Helsinki, Finland ⁵⁷Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA ⁵⁸Health Center, Department of Internal Medicine, Keio University, Tokyo, Japan ⁵⁹Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children's Hospital, Boston, Massachusetts, USA ⁶⁰Departments of Pediatrics and Genetics, Harvard Medical School, Boston, Massachusetts, USA ⁶¹Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA ⁶²Cell Biology Telethon Kids Institute, The University of Western Australia, Subiaco, Western Australia, Australia ⁶³Ontario Institute for Cancer Research, Toronto, Ontario, Canada ⁶⁴AbbVie Inc., Redwood City, California, USA ⁶⁵Busselton Population Medical Research Institute, Perth, Western Australia, Australia ⁶⁶School of Population and Global Health, University of Western Australia, Nedlands, Western Australia, Australia ⁶⁷Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland ⁶⁸University of Basel, Basel, Switzerland ⁶⁹Department of Biology, Medical Genetics and Ecology, Kursk State Medical University, Kursk, Russian Federation ⁷⁰The Generation R Study

Group, Department of Pediatrics and Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands ⁷¹Department of Pulmonary Physiology and Sleep Medicine, Busselton Population Medical Research Institute, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia ⁷²School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia ⁷³Department of Medical Sciences: Respiratory, Allergy & Sleep Research, Uppsala University, Uppsala, Sweden ⁷⁴Department of Epidemiology and Biostatistics, MRC–PHE Centre for Environment & Health, School of Public Health, Imperial College London, London, UK ⁷⁵Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland ⁷⁶Biocenter Oulu, University of Oulu, Oulu, Finland ⁷⁷Unit of Primary Care, Oulu University Hospital, Oulu, Finland ⁷⁸MRC-PHE Centre for Environment and Health, Imperial College London, London, UK ⁷⁹School of Science and Health, Western Sydney University, Sydney, New South Wales, Australia ⁸⁰Faculty of Medicine, University of Iceland, Reykjavik, Iceland ⁸¹Department of Pediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO), Regensburg, Germany ⁸²Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland ⁸³Department of Anesthesiology, Perioperative and Pain Medicine, Division of Critical Care Medicine, Boston Children's Hospital, Boston, Massachusetts, USA ⁸⁴Department of Anaesthesia, Harvard Medical School, Boston, Massachusetts, USA ⁸⁵Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa, Russian Federation ⁸⁶University of Groningen, University Medical Center Groningen, Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, Groningen, the Netherlands ⁸⁷Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands ⁸⁸Department of Pediatrics, The University of Alberta, Edmonton, Alberta, Canada ⁸⁹RIKEN Center for Integrative Medical Sciences, Yokohama, Japan ⁹⁰Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA ⁹¹Division of Allergy and Clinical Immunology, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA ⁹²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden ⁹³Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland ⁹⁴Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium ⁹⁵Department of Pulmonary Medicine, University of Turku and Turku University Hospital, Turku, Finland ⁹⁶Département des Sciences Fondamentales, Université du Québec à Chicoutimi, Chicoutimi, Quebec, Canada ⁹⁷Centre de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, Québec, Canada ⁹⁸McGill University and Genome Quebec Innovation Centre, Montréal, Quebec, Canada ⁹⁹Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany ¹⁰⁰Max-Delbrück-Centrum (MDC) for Molecular Medicine, Berlin, Germany ¹⁰¹Pediatric Allergology, Experimental and Clinical Research Center, Charité Universitätsmedizin, Berlin, Germany ¹⁰²Department of Clinical Chemistry, Fimlab Laboratories, University of Tampere Faculty of Medicine and Life Sciences, Tampere, Finland ¹⁰³Department of Public

Health Sciences, Henry Ford Health System, Detroit, Michigan, USA ¹⁰⁴Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA ¹⁰⁵Division of General Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA ¹⁰⁶National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA ¹⁰⁷Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA ¹⁰⁸Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia ¹⁰⁹Division of Allergy & Clinical Immunology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA ¹¹⁰Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan ¹¹¹Bristol Bioresource Laboratories, School of Social and Community Medicine, University of Bristol, Bristol, UK ¹¹²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark ¹¹³Department of Medicine, Stanford University School of Medicine, Stanford, California, USA ¹¹⁴Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden ¹¹⁵Sachs Children's Hospital, Stockholm, Sweden ¹¹⁶Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia ¹¹⁷Schools of Population Health and Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia ¹¹⁸Center for Applied Genomics and Precision Medicine, Duke University School of Medicine, Durham, North Carolina, USA ¹¹⁹University of Groningen, University Medical Center Groningen, Department of Pulmonology, Groningen, the Netherlands ¹²⁰Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan ¹²¹Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA ¹²²The National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA ¹²³Department of Faculty Pediatrics, Siberian State Medical University, Tomsk, Russian Federation ¹²⁴Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology and Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA ¹²⁵The Stanley Center for Psychiatric Research and Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA ¹²⁶Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA ¹²⁷Department of Clinical Physiology and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, Finland ¹²⁸Department of Medical and Molecular Genetics, King's College London, London, UK ¹²⁹Respiratory Medicine, Murdoch Children's Research Institute, Melbourne, Victoria, Australia ¹³⁰Hubert department of Global Health, Mory University, Atlanta, Georgia, USA ¹³¹Center for Population Health Research, National Institute of Public Health, Cuernavaca, Mexico ¹³²Department of Psychiatry, Kern Medical, Bakersfield, California, USA ¹³³Department of Public Health, Section for Environment, Occupation & Health, Aarhus University, Aarhus, Denmark ¹³⁴MRC Epidemiology Unit, University of Cambridge School of Clinical

Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK ¹³⁵Department of Faculty Therapy, Siberian State Medical University, Tomsk, Russian Federation ¹³⁶University Hospital of South Manchester, National Health Service (NHS) Foundation Trust, Manchester, UK ¹³⁷Institut National de la Santé et de la Recherche Médicale (INSERM) U1209, Institute for Advanced Biosciences, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Grenoble, France ¹³⁸Université de Grenoble Alpes / CNRS UMR5309, Institute for Advanced Biosciences, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Grenoble, France ¹³⁹Division of Pulmonary and Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA ¹⁴⁰Population Health Research Institute, St George's University of London, London, UK ¹⁴¹Netherlands Healthcare Inspectorate, The Hague, The Netherlands ¹⁴²Department of Internal Medicine, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands ¹⁴³Institute for Respiratory Health and Harry Perkins Institute of Medical Research, University of Western Australia and The Lung Health Clinic, Nedlands, Western Australia, Australia ¹⁴⁴Division of Metabolic Diseases and Nutritional Medicine, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany ¹⁴⁵Department of Medical Science Mathematics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan ¹⁴⁶The Generation R Study Group, Department of Pediatrics - Division of Respiratory Medicine and Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands ¹⁴⁷Department of Pediatrics, Marien-Hospital Wesel, Wesel, Germany ¹⁴⁸Dr. Von Hauner Children's Hospital, Ludwig Maximilians University Munich, Munich, Germany ¹⁴⁹Member of the German Center for Lung Research, Germany ¹⁵⁰University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands ¹⁵¹Undergraduate Training and Education Center (UTEC), Jackson Heart Study, Tougaloo College, Jackson, Mississippi, USA ¹⁵²Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden ¹⁵³Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan, USA ¹⁵⁴Department of Internal Medicine, Henry Ford Health System, Detroit, Michigan, USA ¹⁵⁵School of Nursing, University of Michigan, Ann Arbor, Michigan, USA ¹⁵⁶Department of Human Genetics, The University of Chicago, Chicago, Illinois, USA ¹⁵⁷Departments of Statistics, Human Genetics and Medicine, Section of Genetic Medicine, The University of Chicago, Chicago, Illinois, USA

Acknowledgments

We thank all participants who provided data for each study and to our valued colleagues who contributed to data collection and phenotypic characterization of clinical samples, genotyping and analysis of individual datasets. Detailed acknowledgements and funding for individual studies can be found in the Supplementary Note.

References

1. Akinbami LJ, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS Data Brief. 2012;1–8.
2. Duffy DL, Martin NG, Battistutta D, Hopper JL, Mathews JD. Genetics of asthma and hay fever in Australian twins. Am Rev Respir Dis. 1990; 142:1351–8. [PubMed: 2252253]
3. Welter D, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014; 42:D1001–6. [PubMed: 24316577]
4. Igartua C, et al. Ethnic-specific associations of rare and low-frequency DNA sequence variants with asthma. Nat Commun. 2015; 6:5965. [PubMed: 25591454]
5. Bouzigon E, et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. N Engl J Med. 2008; 359:1985–94. [PubMed: 18923164]
6. Galanter JM, et al. Genome-wide association study and admixture mapping identify different asthma-associated loci in Latinos: the Genes-environments & Admixture in Latino Americans study. J Allergy Clin Immunol. 2014; 134:295–305. [PubMed: 24406073]
7. Hirota T, et al. Genome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese population. Nat Genet. 2011; 43:893–6. [PubMed: 21804548]
8. Ferreira MA, et al. Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype. J Allergy Clin Immunol. 2014; 133:1564–71. [PubMed: 24388013]
9. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539–58. [PubMed: 12111919]
10. Grundberg E, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet. 2012; 44:1084–9. [PubMed: 22941192]
11. Westra HJ, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013; 45:1238–43. [PubMed: 24013639]
12. The GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015; 348:648–60. [PubMed: 25954001]
13. Liang L, et al. A cross-platform analysis of 14,177 expression quantitative trait loci derived from lymphoblastoid cell lines. Genome Res. 2013; 23:716–26. [PubMed: 23345460]
14. Hao K, et al. Lung eQTLs to help reveal the molecular underpinnings of asthma. PLoS Genet. 2012; 8:e1003029. [PubMed: 23209423]
15. Noguchi E, et al. Genome-wide association study identifies *HLA-DP* as a susceptibility gene for pediatric asthma in Asian populations. PLoS Genet. 2011; 7:e1002170. [PubMed: 21814517]
16. Ding L, et al. Rank-based genome-wide analysis reveals the association of ryanodine receptor-2 gene variants with childhood asthma among human populations. Hum Genomics. 2013; 7:16. [PubMed: 23829686]
17. Sleiman PM, et al. Variants of *DENND1B* associated with asthma in children. N Engl J Med. 2010; 362:36–44. [PubMed: 20032318]
18. Himes BE, et al. Genome-wide association analysis identifies *PDE4D* as an asthma-susceptibility gene. Am J Hum Genet. 2009; 84:581–93. [PubMed: 19426955]
19. Torgerson DG, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet. 2011; 43:887–92. [PubMed: 21804549]
20. Bonnelykke K, et al. A genome-wide association study identifies *CDHR3* as a susceptibility locus for early childhood asthma with severe exacerbations. Nat Genet. 2014; 46:51–5. [PubMed: 24241537]
21. Ferreira MA, et al. Identification of *IL6R* and chromosome 11q13.5 as risk loci for asthma. Lancet. 2011; 378:1006–14. [PubMed: 21907864]
22. Moffatt MF, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010; 363:1211–21. [PubMed: 20860503]
23. Zeller T, et al. Genetics and beyond—the transcriptome of human monocytes and disease susceptibility. PLoS One. 2010; 5:e10693. [PubMed: 20502693]

24. Kundaje A, et al. Integrative analysis of 111 reference human epigenomes. *Nature*. 2015; 518:317–30. [PubMed: 25693563]
25. Raychaudhuri S, et al. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. *PLoS Genet*. 2009; 5:e1000534. [PubMed: 19557189]
26. Hong SW, Kim S, Lee DK. The role of Bach2 in nucleic acid-triggered antiviral innate immune responses. *Biochem Biophys Res Commun*. 2008; 365:426–32. [PubMed: 17991429]
27. Yang M, He RL, Benovic JL, Ye RD. Beta-Arrestin1 interacts with the G-protein subunits beta1gamma2 and promotes beta1gamma2-dependent Akt signalling for NF-kappaB activation. *Biochem J*. 2009; 417:287–96. [PubMed: 18729826]
28. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. *Nat Genet*. 2011; 43:1082–90. [PubMed: 21946350]. [PubMed: 21946350]
29. Goenka S, Kaplan MH. Transcriptional regulation by *STAT6*. *Immunol Res*. 2011; 50:87–96. [PubMed: 21442426]
30. Qian X, Gao Y, Ye X, Lu M. Association of *STAT6* variants with asthma risk: a systematic review and meta-analysis. *Hum Immunol*. 2014; 75:847–53. [PubMed: 24952213]
31. Wang Y, Tong X, Ye X. Ndfip1 negatively regulates RIG-I-dependent immune signaling by enhancing E3 ligase Smurf1-mediated MAVS degradation. *J Immunol*. 2012; 189:5304–13. [PubMed: 23087404]
32. Venuprasad K, Zeng M, Baughan SL, Massoumi R. Multifaceted role of the ubiquitin ligase Itch in immune regulation. *Immunol Cell Biol*. 2015; 93:452–60. [PubMed: 25582340]
33. Javierre BM, et al. Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters. *Cell*. 2016; 167:1369–1384. e19. [PubMed: 27863249]
34. Barnes PJ. Pathophysiology of allergic inflammation. *Immunol Rev*. 2011; 242:31–50. [PubMed: 21682737]
35. Vicente CT, et al. Long-Range Modulation of *PAG1* Expression by 8q21 allergy risk variants. *Am J Hum Genet*. 2015; 97:329–36. [PubMed: 26211970]
36. Davison LJ, et al. Long-range DNA looping and gene expression analyses identify *DEX1* as an autoimmune disease candidate gene. *Hum Mol Genet*. 2012; 21:322–33. [PubMed: 21989056]
37. Wang L, et al. CPAG: software for leveraging pleiotropy in GWAS to reveal similarity between human traits links plasma fatty acids and intestinal inflammation. *Genome Biol*. 2015; 16:190. [PubMed: 26374098]
38. Rottem M, Shoenfeld Y. Asthma as a paradigm for autoimmune disease. *Int Arch Allergy Immunol*. 2003; 132:210–4. [PubMed: 14646381]
39. Li X, et al. Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases. *J Allergy Clin Immunol*. 2012; 130:861–8. e7. [PubMed: 22694930]
40. Hayes JE, et al. Tissue-Specific enrichment of lymphoma risk loci in regulatory elements. *PLoS One*. 2015; 10:e0139360. [PubMed: 26422229]
41. Liang L, et al. An epigenome-wide association study of total serum immunoglobulin E concentration. *Nature*. 2015; 520:670–4. [PubMed: 25707804]
42. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med*. 2012; 18:716–25. [PubMed: 22561835]
43. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986; 7:177–88. [PubMed: 3802833]
44. Yang J, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet*. 2012; 44:369–75. S1–3. [PubMed: 22426310]
45. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. *Annu Rev Genomics Hum Genet*. 2009; 10:387–406. [PubMed: 19715440]
46. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. 2010; 26:841–2. [PubMed: 20110278]

47. Raychaudhuri S. VIZ-GRAIL: visualizing functional connections across disease loci. *Bioinformatics*. 2011; 27:1589–90. [PubMed: 21505031]
48. So HC, Gui AH, Cherny SS, Sham PC. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. *Genet Epidemiol*. 2011; 35:310–7. [PubMed: 21374718]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1. Manhattan plots of the results of European-ancestry and multi-ancestry random-effects meta-analyses of asthma risk. (a) The European-ancestry meta-analysis pertains to 19,954 cases and 107,715 controls. (b) The multi-ancestry meta-analysis pertains to 23,948 cases and 118,538 controls. Each locus is annotated by its cytogenetic band location. The x axis represents chromosomal location and the y axis represents $-\log_{10}(P)$ for tests of association between SNPs and asthma. Black, previously known loci; red, new loci identified in the European-ancestry meta-analysis; blue, additional new loci identified in the multi-ancestry meta-analysis. The dashed horizontal line denotes $P=5 \times 10^{-8}$.




Figure 2. GRAIL²⁵ circle plot of connectivity between genes at asthma risk loci. The 17 asthma risk loci are along the outer ring (the 10p14 locus was ignored because it corresponds to a gene desert); the internal ring represents the genes at these loci. The width of the lines drawn between genes corresponds to the strength of the literature-based connectivity, with thicker lines representing stronger connections.

Table 1
Genetic loci associated with asthma in European-ancestry and multi-ancestry meta-analyses

Locus ^a	No. Sig SNPs Eur-anc/ Multi-anc ^b	rsID	Position ^c	Nearby genes ^d	Allele ^e	European-ancestry meta-analysis				Multi-ancestry meta-analysis					
						EAF	OR	95% CI	P _{random}	P _{het}	OR	95% CI	P _{random}	P _{het}	P _{ethnic}
New asthma susceptibility loci															
5q31.3	0 / 11	rs7705042	141,492,419	<i>NDPFI, GNDPAL, SPRY4</i>	C/A	0.63	1.08	1.05–1.11	1.6 × 10 ⁻⁶	0.07	1.09	1.06–1.12	7.9 × 10 ⁻⁹	0.11	0.55
6p22.1	8 / 5	rs1233578	28,712,247	<i>GPX5, TRIM27</i>	A/G	0.13	1.11	1.07–1.15	5.3 × 10 ⁻⁹	0.82	1.09	1.05–1.12	5.9 × 10 ⁻⁷	0.56	0.003
6q15	26 / 26	rs2325291	90,986,686	<i>BACH2, GATA10, MAP3K7</i>	G/A	0.33	0.91	0.89–0.93	8.6 × 10 ⁻¹³	0.78	0.91	0.89–0.94	2.2 × 10 ⁻¹²	0.80	0.39
12q13.3	0 / 1	rs167769	57,503,775	<i>STAT6, NAB2, LRP1</i>	C/T	0.40	1.08	1.05–1.11	1.6 × 10 ⁻⁷	0.19	1.08	1.05–1.11	3.9 × 10 ⁻⁹	0.31	0.85
17q21.33	4 / 3	rs17637472	47,461,433	<i>ZNF652, PHB</i>	G/A	0.39	1.08	1.05–1.11	3.3 × 10 ⁻⁹	0.56	1.08	1.05–1.11	6.6 × 10 ⁻⁹	0.35	0.12
New signals at loci previously associated with asthma in ancestry-specific populations															
6p21.33	66 / 53	rs2855812	31,472,720	<i>MICB, HCP5, MCCD1</i>	G/T	0.23	1.10	1.06–1.13	1.7 × 10 ⁻⁸	0.23	1.10	1.07–1.13	8.9 × 10 ⁻¹²	0.39	0.58
10p14	3 / 6	rs2589561	9,046,645	<i>GATA3, CELF2</i>	A/G	0.82	0.90	0.87–0.94	1.4 × 10 ⁻⁸	0.78	0.91	0.88–0.94	3.5 × 10 ⁻⁹	0.82	0.25
Asthma signals previously reported for asthma plus hay fever															
8q21.13	1 / 28	rs12543811	81,278,885	<i>TPD52, ZBTB10</i>	G/A	0.66	0.93	0.91–0.95	3.4 × 10 ⁻⁸	0.47	0.92	0.90–0.95	1.1 × 10 ⁻¹⁰	0.54	0.24
16p13.13	12 / 13	rs17806299	11,199,980	<i>CLEC16A, DEX1, SOCS1</i>	G/A	0.20	0.90	0.88–0.93	2.1 × 10 ⁻¹⁰	0.51	0.91	0.88–0.94	2.7 × 10 ⁻¹⁰	0.49	0.58
Known asthma loci															
2q12	133 / 144	rs1420101	102,957,716	<i>IL1RL1, IL1RL2, IL18R1</i>	C/T	0.37	1.12	1.10–1.15	9.1 × 10 ⁻²⁰	0.63	1.12	1.09–1.15	3.9 × 10 ⁻²¹	0.61	0.64
5q22.1	35 / 32	rs10455025	110,404,999	<i>SLC25A46, TSLP</i>	A/C	0.34	1.15	1.12–1.18	2.0 × 10 ⁻²⁵	0.53	1.15	1.12–1.18	9.4 × 10 ⁻²⁶	0.57	0.27
5q31	33 / 62	rs20541	131,995,964	<i>IL13, RAD50, IL4</i>	A/G	0.79	0.89	0.86–0.91	1.4 × 10 ⁻¹⁴	0.73	0.89	0.87–0.92	5.0 × 10 ⁻¹⁶	0.77	0.62
6p21.32	101 / 124	rs9272346	32,604,372	<i>HLA-DRB1, HLA-DQA1</i>	G/A	0.56	1.16	1.13–1.19	4.8 × 10 ⁻²⁸	0.46	1.16	1.12–1.19	5.7 × 10 ⁻²⁴	0.14	0.43
9p24.1	65 / 71	rs992969	6,209,697	<i>RANBP6, IL33</i>	A/G	0.75	0.85	0.82–0.88	1.1 × 10 ⁻¹⁷	0.008	0.86	0.83–0.88	7.2 × 10 ⁻²⁰	0.02	0.57
11q13.5	4 / 5	rs7927894	76,301,316	<i>C11orf30, LRRRC32</i>	C/T	0.37	1.10	1.07–1.13	3.5 × 10 ⁻¹¹	0.38	1.10	1.08–1.13	2.2 × 10 ⁻¹⁴	0.56	0.47
15q22.2	9 / 14	rs11071558	61,069,421	<i>RORA, NARG2, VPS13C</i>	A/G	0.14	0.89	0.85–0.92	1.9 × 10 ⁻¹⁰	0.44	0.89	0.86–0.92	1.3 × 10 ⁻⁹	0.19	0.06
15q22.33	13 / 13	rs2033784	67,449,660	<i>SMAD3, SMAD6, AAGAB</i>	A/G	0.30	1.11	1.08–1.14	2.5 × 10 ⁻¹⁴	0.75	1.10	1.08–1.13	7.4 × 10 ⁻¹⁵	0.76	0.48
17q12–21	160 / 198	rs2952156	37,876,835	<i>ERBB2, PGAP3, C17orf37</i>	A/G	0.70	0.86	0.84–0.88	7.6 × 10 ⁻²⁹	0.55	0.87	0.84–0.89	2.2 × 10 ⁻³⁰	0.52	0.35

SNP *P*-values for association with asthma are based on random-effects meta-analysis using Stata. A total of 878 SNPs, belonging to 18 loci, reached genome-wide significance (*P*_{random} < 5 × 10⁻⁸). Each locus, in this table, is represented by the SNP with the strongest evidence for association in the European-ancestry (127,669 subjects) or multi-ancestry meta-analysis (142,486 subjects from European-

ancestry, African-ancestry, Japanese and Latino populations). The Cochran's Q test was used to test for heterogeneity in SNP effect sizes across studies (P_{het}) and to test for a difference between the four ancestry-specific summary effects (P_{ethnic}), EAF, effect allele frequency; OR, odds (log-additive) ratio; 95% CI, 95% confidence interval.

^a Cytogenetic band;

^b Number of genome-wide significant SNPs ($P_{random} < 5 \times 10^{-8}$) at each locus in European-ancestry meta-analysis/multi-ancestry meta-analysis;

^c SNP position, build 37.

^d The gene where eventually the SNP lies is first indicated, followed by the previous gene and next gene;

^e Reference/Effect allele.

Table 2

Main characteristics of the nine loci harboring novel associations with asthma

Locus ^a	Location of lead SNP ^b	Cis-eQTLs in blood (B) and lung tissue (L)	Association with allergy-related and lung function phenotypes	Association with auto-immune diseases and other immune-related traits
New asthma susceptibility loci				
5q31.3	<i>NDFIP1</i> (intron)	B: <i>NDFIP1</i> (2.7×10^{-9})		IBD
6p22.1	Intergenic	B: <i>ZSCAN12</i> (3.0×10^{-8}) L: <i>ZSCAN31</i> (6.5×10^{-11})	Lung function	
6q15	<i>BACH2</i> (intron)	B: <i>BACH2</i> (3.0×10^{-10})		MS, T1D, CD, IBD, V, IGG
12q13.3	<i>STAT6</i> (intron)	B: <i>STAT6</i> (9.8×10^{-198}) L: <i>STAT6</i> (3.7×10^{-37})	IgE (total, specific) Lung function	Pso, ISP_IFN
17q21.33	Intergenic	B: <i>GNGT2</i> (2.1×10^{-52})	Atopic dermatitis	ISP_IL2
New asthma signals at loci previously associated with asthma in ancestry-specific populations				
6p21.33	<i>MICB</i> (intron)	B: <i>TNF</i> (4.8×10^{-14}), <i>LST1</i> (1.0×10^{-13}), <i>HLA-C</i> (3.2×10^{-13}), <i>LTA</i> (1.0×10^{-10}) L: <i>MICB</i> (4.6×10^{-13})	IgE (total, specific), Self-reported allergy, Atopic dermatitis, Lung Function	SLE, UC, RA, IBD, BS, GD, SS, AS, Pso, UC, V, WBC, MoC, DS, HIV-1, SJS, HB, HBV, IMN, CD4:CD8 ratio, HIV-1C
10p14	Intergenic	None	Self-reported allergy	RA, ISP_IL1B, ISPV
Asthma signals previously reported for asthma plus hay fever				
8q21.13	Intergenic	None	Atopic dermatitis, Asthma + hay fever Self-reported allergy	RA
16p13.13	<i>CLEC16A</i> (intron)	B: <i>DEXI</i> (2.2×10^{-43})	Atopic dermatitis, Asthma + hay fever	T1D, PBC, MS, RA, IBD, CD, LEP

At each of the nine loci harboring novel associations with asthma, cis-genes whose expression (e-QTLs) is associated with the lead asthma-associated SNPs (shown in Table 1) or SNPs in LD ($r^2 \geq 0.5$) with the lead SNPs were searched using six eQTL databases from whole blood^{11,12}, lymphoblastoid cell lines^{10,13}, monocytes²³ and lung^{12,14}; only genes with the strongest associations (P -value $< 5 \times 10^{-8}$, as shown in parentheses) are presented here (Supplementary Table 16 for details). Overlap of these nine loci with associations with allergy-related and lung function phenotypes as well as with auto-immune diseases and other immune-related traits was annotated using the GWAS catalog³;

IBD=Inflammatory bowel diseases (Crohn's disease), MS=multiple sclerosis, T1D=type 1 diabetes, CD=celiac disease, V=vitiligo, IGG=IgG Glycosylation, Pso=psoriasis, ISP_IFN=Immune Response to Smallpox (secreted IFN-alpha), ISP_IL2 Immune Response to Smallpox (secreted IL2), SLE=Systemic Lupus Erythematosus, UC=Ulcerative colitis, RA=Rheumatoid arthritis, BS=Behçet syndrome, GD=Grave's disease, SS=Systemic sclerosis, AS=Ankylosing spondylitis, WBC=White Blood cell count, MoC=monocyte count, DS=Dengue shock, HIV-1=HIV-1-susceptibility, SJS=Stevens-Johnson syndrome, HB=Hepatitis B infection, HBV=Hepatitis B vaccine response, IMN=Idiopathic membranous nephropathy, CD4:CD8=CD4:CD8 lymphocyte ratio, HIV-1C= HIV-1 control, ISP_IL1B=Immune Response to Smallpox (secreted IL-1 beta), ISPV=Immune response to smallpox vaccine (IL-6), PBC=Primary biliary cirrhosis, LEP=Leprosy.

^aCytogenetic band;

^bThe protein coding genes flanking intergenic SNPs are shown in Table 1.

Table 3

Overlap of TAGC asthma-associated SNPs with GWAS catalog association signals by disease group

Disease Group	Number of GWAS catalog association signals	Number of SNPs associated with asthma at $P_{\text{random}} 10^{-4}$ in the multi-ancestry meta-analysis	<i>P</i> -value for overlap
Cardiovascular	743	20	7.8×10^{-42}
Body size and morphology	346	2	5.0×10^{-4}
Immune/Autoimmune	480	49	3.0×10^{-129}
Nervous system	242	4	1.4×10^{-8}
Blood	594	10	1.3×10^{-19}
Neuropsychiatric	114	5	1.5×10^{-12}
Cancer	417	7	4.0×10^{-14}
Endocrine system	276	2	4.0×10^{-4}
Digestive system	347	16	1.4×10^{-37}
Eyes	177	2	2.0×10^{-4}
Respiratory system	85	2	3.6×10^{-5}
Infectious disease/Infection	104	2	5.3×10^{-5}
Urinary system	144	1	1.5×10^{-2}
Alcohol, smoking, and illicit substances	30	0	1
Musculoskeletal system	132	0	1

Overlap of TAGC asthma-associated SNPs with association signals of all diseases/traits in the GWAS catalog³ was investigated for all TAGC SNPs having $P_{\text{random}} 10^{-4}$ in the multi-ancestry meta-analysis; diseases from the GWAS catalog were grouped according to the disease classification proposed by Wang *et al.*³⁷ (note that the “Digestive system” group includes Crohn’s Disease, a subtype of Inflammatory Bowel Disease). The significance of overlap was estimated by the binomial tail probability for observing the shown number of TAGC asthma SNPs among the number of SNPs reported in the GWAS catalog for a group of diseases (for example, the probability of observing 20 or more asthma SNPs with $P_{\text{random}} 10^{-4}$ among the 743 cardiovascular SNPs is shown in the last column); a conservative Bonferroni adjusted significance threshold for enrichment in shared associations is $0.05/15=0.003$ (for the 15 disease groups investigated).

Table 4

Enrichment of asthma risk loci in promoter and enhancer marks and DNase I-hypersensitive sites

Type of regulatory elements	Proportion of all cell types (blood cell types) showing enrichment with a given false discover rate (FDR)	
	FDR 10%	FDR 5%
All promoter states	6% (26%)	0
Active promoter states	13% (33%)	0
All enhancer states	57%(100%)	44%(89%)
Active enhancer states	66% (100%)	50%(100%)
DNase I-hypersensitive sites	16% (50%)	12%(40%)

The co-localization of SNPs at asthma risk loci with regulatory elements (promoters, enhancers, DNase I-hypersensitive sites) was assessed at 16 asthma-loci identified by this study (Table 1); the 6p21.33 and 6p21.32 loci that encompass the HLA region were excluded because of the high amount of variability and LD in this region. Enhancer and promoter states were defined using the ChromHMM 15-state model applied to functional data of 127 ROADMAP and ENCODE reference epigenomes in various cell types (including 27 leukocytes)²⁴. DNase I hypersensitivity sites were identified in 51 cell types (including 10 leukocytes)²⁴. Empirical-*P*-values for enrichment were obtained using 10,000 Monte-Carlo simulations of random sets of SNPs matching the original set of asthma-associated SNPs⁴⁰; Benjamini-Hochberg's FDR was calculated to correct for multiple testing (Online Methods for details).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript